

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 06275-150003	Application No. 09/670,457
	Applicant Carl-Axel Bauer et al.			
	Filing Date		Group Art Unit 1614	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	5,795,564	8/18/1998	Aberg et al.			03/07/1996
	AB						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
	AC	WO 93/1173	06/24/93	PCT			Yes	No
	AD	0 416 950 A1	03/13/1991	Europe				
	AE	0 416 951 A1	03/13/1991	Europe				

Other Documents (Include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AF	CA 126:259329 Renkema et al.
	AG	C. Wyser et al., "Neue Aspekte in der Behandlung des Asthma bronchiale und chronisch obstruktiver Lungenkrankheiten", 1997, Schweiz Med Wochenschr, Volume 127 page 885-page 890
	AH	Jean H. Marsac, Fotis D. Vlastos, and Jacques G. Lacroque "Inhaled beta adrenergic agonists and inhaled steroids in the treatment of asthma" Annals of Allergy September 1989, Vol. 63, number 3, pages 220-224
	AI	Francis P.V. Maesen, M.D., Ph.D., F.C.C.P. Joseph J. Smeets, Hendrik L. L. Gubbelsmans, M.D., and Petra G. M. A. Zweers, M.D. "Formoterol in the Treatment of Nocturnal Asthma" Chest 98 4 October 1990 pages 886-870
	AJ	Francis P.V. Maesen, M.D., Ph.D., F.C.C.P., Joseph J. Smeets; Hendrik L. L. Gubbelsmans, M.D., and Petra G.M. A. Zweers, M.D. "Bronchodilator Effect of Inhaled Formoterol vs. Salbutamol Over 12 Hours" Chest/97/3/March 1990
	AK	Romain A. Pauwels, M.D., Claes-Goran Lofdahl, M.D., Peter J. Barnes, M.D., and Anders Ullman, M.D. "Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma" Vol. 337 Number 20, November 13, 1997
	AL	Curriculum Vitae of Charles Richard William Beasley
	AM	Statutory Declaration of Charles Richard William Beasley
	AN	New Ethicals Catalogue, December 1990, No. 3 p. 50
	AO	Additive effects of Budesonide and Formoterol in Reducing Severe Asthma Exacerbations Over 12 Months, O'Byrne et al. On behalf of international study group and Astra Draco AB Lund Sweden
	AP	Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma, Pauwels et al., Massachusetts Medical Society, November 13, 1997, Vol. 337, Number 20, p. 1405
	AQ	Response by Astra to EPO, dated November 22, 1995

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-150003	Application No.
	Applicant Carl-Axel Bauer et al.		
	Filing Date	Group Art Unit	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AL							
	AM							
	AN							
	AO							
	AP							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AQ	Huib A.M. Kerstjens, MD., et al. "A Comparison of Bronchodilator Therapy with or without Inhaled Corticosteroid Therapy for Obstructive Airways Disease" November 12, 1992, The New England Journal of Medicine, Vol. 327 number 20, pages 1413-1419.
	AR	
	AS	
	AT	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)